BACKGROUND: Reactive oxygen species (ROS) and glutathione (GSH) depletion contribute to organ injury after bone marrow transplantation (BMT). Keratinocyte growth factor (KGF) ameliorates graft-versus-host disease (GVHD)-associated organ injury in murine BMT models. METHODS: B10.BR mice received total body irradiation (TBI; day -1) +/- cyclophosphamide (Cy; 120 mg/kg/day i.p., days -3 and -2), then were transplanted on day 0 with C57BL/6 bone marrow + spleen cells as a source of GVHD-causing T cells. KGF (5 mg/kg/day subcutaneously [s.c.]) or saline was given on days -6, -5, and -4. Lung and liver GSH and oxidized GSH disulfide (GSSG) levels were measured on days 0 and 5 and glutathione redox potential (Eh) calculated. Organ malondialdehyde (MDA) was determined on day 5 as an index of ROS-mediated lipid peroxidation. RESULTS: In lung, TBI+BMT oxidized GSH Eh and increased MDA. Cy further oxidized lung GSH Eh. In liver, neither BMT regimen altered GSH redox status or MDA. KGF prevented the decrease in lung GSH after TBI+Cy and decreased lung MDA after both TBI and TBI+Cy. KGF increased liver GSH levels and GSH Eh after TBI and GSH Eh after TBI+Cy. CONCLUSIONS: In murine allogeneic BMT, TBI oxidizes the lung GSH redox pool and Cy exacerbates this response by 5 days post-BMT. In contrast, liver GSH redox status is maintained under these experimental conditions. KGF treatment attenuates the Cy-induced decrease in lung GSH, decreases post-BMT lung lipid peroxidation, and improves liver GSH redox indices. KGF may have a therapeutic role to prevent or attenuate GSH depletion and ROS-mediated organ injury in BMT.
BACKGROUND:Reactive oxygen species (ROS) and glutathione (GSH) depletion contribute to organ injury after bone marrow transplantation (BMT). Keratinocyte growth factor (KGF) ameliorates graft-versus-host disease (GVHD)-associated organ injury in murine BMT models. METHODS: B10.BR mice received total body irradiation (TBI; day -1) +/- cyclophosphamide (Cy; 120 mg/kg/day i.p., days -3 and -2), then were transplanted on day 0 with C57BL/6 bone marrow + spleen cells as a source of GVHD-causing T cells. KGF (5 mg/kg/day subcutaneously [s.c.]) or saline was given on days -6, -5, and -4. Lung and liver GSH and oxidized GSH disulfide (GSSG) levels were measured on days 0 and 5 and glutathione redox potential (Eh) calculated. Organ malondialdehyde (MDA) was determined on day 5 as an index of ROS-mediated lipid peroxidation. RESULTS: In lung, TBI+BMT oxidized GSH Eh and increased MDA. Cy further oxidized lung GSH Eh. In liver, neither BMT regimen altered GSH redox status or MDA. KGF prevented the decrease in lung GSH after TBI+Cy and decreased lung MDA after both TBI and TBI+Cy. KGF increased liver GSH levels and GSH Eh after TBI and GSH Eh after TBI+Cy. CONCLUSIONS: In murine allogeneic BMT, TBI oxidizes the lung GSH redox pool and Cy exacerbates this response by 5 days post-BMT. In contrast, liver GSH redox status is maintained under these experimental conditions. KGF treatment attenuates the Cy-induced decrease in lung GSH, decreases post-BMT lung lipid peroxidation, and improves liver GSH redox indices. KGF may have a therapeutic role to prevent or attenuate GSH depletion and ROS-mediated organ injury in BMT.
Authors: Mathangi Srinivasan; Ryan Flynn; Andrew Price; Ann Ranger; Jeffrey L Browning; Patricia A Taylor; Jerome Ritz; Joseph H Antin; William J Murphy; Leo Luznik; Mark J Shlomchik; Angela Panoskaltsis-Mortari; Bruce R Blazar Journal: Blood Date: 2011-11-09 Impact factor: 22.113
Authors: Angela Panoskaltsis-Mortari; Matthias Griese; David K Madtes; John A Belperio; Imad Y Haddad; Rodney J Folz; Kenneth R Cooke Journal: Am J Respir Crit Care Med Date: 2011-05-01 Impact factor: 21.405
Authors: Youngja Park; Tiejun Zhao; Nana Gletsu Miller; Seoung Bum Kim; Carolyn Jonas Accardi; Thomas R Ziegler; Xiaoping Hu; Dean P Jones Journal: Nutrition Date: 2011-09-14 Impact factor: 4.008
Authors: Bruce R Blazar; Daniel J Weisdorf; Todd Defor; Anne Goldman; Thomas Braun; Samuel Silver; James L M Ferrara Journal: Blood Date: 2006-07-11 Impact factor: 22.113
Authors: Ruth Seggewiss; Karin Loré; F Javier Guenaga; Stefania Pittaluga; Joseph Mattapallil; Catherine K Chow; Richard A Koup; Kevin Camphausen; Martha C Nason; Martin Meier-Schellersheim; Robert E Donahue; Bruce R Blazar; Cynthia E Dunbar; Daniel C Douek Journal: Blood Date: 2007-03-20 Impact factor: 22.113
Authors: Ines A Silva; Krystyna Olkiewicz; David Askew; Jacquelyn M Fisher; Meghana N Chaudhary; Kevin M Vannella; Daphne T Deurloo; Sung W Choi; Elizabeth M Pierce; Shawn G Clouthier; Chen Liu; Kenneth R Cooke Journal: Biol Blood Marrow Transplant Date: 2010-02-01 Impact factor: 5.742
Authors: Angela Panoskaltsis-Mortari; Kevin V Tram; Andrew P Price; Christine H Wendt; Bruce R Blazar Journal: Am J Respir Crit Care Med Date: 2007-06-15 Impact factor: 21.405
Authors: Smita S Iyer; Edilson Torres-Gonzalez; David C Neujahr; Mike Kwon; Kenneth L Brigham; Dean P Jones; Ana L Mora; Mauricio Rojas Journal: Stem Cells Int Date: 2010-03-08 Impact factor: 5.443